March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Bevacizumab vs. Ranibizumab: Cost-effectiveness Analysis Accounting for Treatment-Related Complications
Author Affiliations & Notes
  • Chukwuemeka C. Nwanze
    Lab of computer science, MGH, Lab of Computer Science, Chestnut Hill, Massachusetts
  • Footnotes
    Commercial Relationships  Chukwuemeka C. Nwanze, None
  • Footnotes
    Support  Newman's Own, REI, NIH training grant
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1415. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chukwuemeka C. Nwanze; Bevacizumab vs. Ranibizumab: Cost-effectiveness Analysis Accounting for Treatment-Related Complications. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1415.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered.

Methods: : A Markov model was developed to assess the cost effectiveness of each of the following protocols: monthly ranibizumab, monthly bevacizumab, as-needed ranibizumab and as-needed bevacizumab. Direct costs and utilities were assessed from the perspective of a third-party payer or an insurance company. Cost effectiveness was evaluated in 2011 US dollars per quality-adjusted life year (QALY).

Results: : Considering the treatment costs of severe medical and ocular adverse events, the cost effectiveness of each protocol is as follows: monthly ranibizumab $63,333 /QALY, ranibizumab as needed $18,571/QALY, bevacizumab monthly $2,676/QALY and bevacizumab as needed $3,333/QALY. Sensitivity analysis of the treatment costs of medical and ocular adverse events demonstrated minimal impact on relative cost-effectiveness.

Conclusions: : At current prices, monthly bevacizumab is the most cost-effective anti-VEGF AMD treatment protocol. Ranibizumab is as cost effective as bevacizumab at a maximum price of $158 per dose.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.